Table 1.
BML Case reports 1986–2012: Hormonal Treatment and Disease Response
| Case Reports | Treatment: GnRH agonism | Response |
|---|---|---|
| Hague, 1986 (35) | Buserelin × 3 months | + |
| Maheux, 1987 (48) | Buserelin × 6 months | 0, C |
| Jacobson, 1995 (30) | Buserelin × 42 months | +, C |
| Takemura, 1996 (43) | BSO + Buserelin × 20 months | 0, C |
| Tietze, 2000 (8) | GnRH agonist × 24 months | + |
| Alessi, 2003 (49) | Goserelin × 12 months | 0 |
| Nardo, 2003 (50) | GnRH agonist × 6 months | 0, C |
| Chan, 2005 (51) | Triptorelin × 3 months | + |
| Egberts, 2006 (52) | GnRH agonist × 12 months | 0, C |
| Arif, 2006 (42) | Gosrelin × 6 months | + |
| Tori, 2008 (53) | GnRH agonist × 10 months | + |
| Bodner-Adler, 2009 (54) | GnRH agonist × 6 months | 0 |
| Mizuno, 2011 (40) | GnRH agonist × 3 years | 0 |
| Silva, 2012 (55) | Goserelin × 2 months → BSO | − |
| Taveira-DaSilva, 2012 (56) | Lupron × 12 months | + |
|
| ||
| Treatment: Aromatase inhibition | ||
| Rivera, 2004 (24) | Raloxifene + Anastrazole × 24 months | +, C |
| Lupron + Anastrazole × 60 months | +, C | |
| Nasu, 2009 (57) | TAH/BSO→Anastrazole × 15 months | 0 |
| Yoon, 2011 (58) | TAH/BSO →Anastrazole × 4 months | + |
| Xiao, 2012 (59) | TAH/BSO→Anastrazole × 12 months | + |
|
| ||
| Treatment: Selective Estrogen Receptor Modulation | ||
| Evans, 1986 (12) | Tamoxifen × 4 months | − |
| Jacobson, 1995 (30) | Tamoxifen + Medroxyprogesterone × 9 months | −, S |
| Shin, 1996 (60) | Tamoxifen × unknown duration | −, C |
| Rivera, 2004 (24) | Tamoxifen × unknown duration | −, S |
| Kishore, 2004 (61) | Tamoxifen × 60 months | +, C |
| Benetti-Pinto, 2006 (33) | Raloxifene × 14 months | + |
| Jo, 2006 (62) | TAH/BSO + Tamoxifen × unknown duration | + |
| Awonuga, 2008 (16) | Tamoxifen × 1 month | − |
| Vaquero, 2009 (3) | Tamoxifen × 1 month | −, S |
| Ahmad, 2011 (63) | Tamoxifen × 6 months | − |
| Wongsripuemtet, 2012 (64) | Tamoxifen × 2 months | − |
|
| ||
| Treatment: Progesterone | ||
| Cramer, 1980 (22) | Progesterone × unknown duration | − |
| Stephenson, 1984 (65) | BSO→Megestrol × 48 months | + |
| Evans, 1986 (12) | Medroxyprogesterone × 3 months | −, S |
| Cho, 1989 (66) | BSO→Progesterone × unknown duration | 0, C |
| Cohen, 1993 (67) | Depo-Provera × 18 months→Megestrol × 8 months | − |
| Motegi, 1993 (68) | Medroxyprogesterone × 48 months | + |
| Hekster, 1994 (69) | Progesterone × unknown duration | −, S |
| Jautzke, 1996 (4) | Medroxyprogesterone × unknown duration | + |
| Goyle, 2003 (70) | Medroxyprogesterone × 3 months | −, S |
| Nardo, 2003 (71) | Provera × unknown duration | 0, C |
| Wentling, 2005 (72) | Megestrol × 3 months | +, C |
| Chan, 2005 (51) | Megestrol × 26 months | 0 |
| Londero, 2008 (73) | Megestrol × 6 months | + |
| Beck, 2012 (23) | Megestrol × 6 months | + |
(+) decrease in disease
(0) stable disease
(−) increase in disease
(C) clinical improvement
(S) no clinical improvement